

REMARKS

Claims 1-5, 7-11, 18-32, 51-53, 69, and 71-100 are pending after entry of this Amendment. Claims 1, 10, 18, 51, 69, 80, and 83 have been amended. Claims 1, 18, 51, 69, 80, and 83 are the only independent claims. The amendments and additions do not include new matter, as set forth in the ensuing section. No additional claim fee is believed to be due.

Support in the Specification

The amendment to claims 1, 18, 51, 69, 80, and 83 simply specifies the three types of KDR⁺-cell separating agents that are disclosed in the specification.

Claim 10 has been amended to eliminate redundancy in view of the amendment made to claim 1, from which claim 10 depends.

For the reasons set forth above, the Applicants respectfully contend that the amendments and additions made herein do not include new matter.

The Applicants understand from telephone conversations with the Examiner that the amendments made herein place the application in condition for allowance. Allowance of each of claims 1-5, 7-11, 18-32, 51-53, 69, and 71-100 is respectfully requested at the earliest possible date.

Respectfully submitted,

CESARE PESCHLE ET AL.

24 December 2002
(Date)

By:

GARY D. COLBY, Ph.D., J.D.

Registration No. 40,961

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

One Commerce Square

2005 Market Street - 22nd Floor

Philadelphia, PA 19103-7086

Telephone: 215-965-1200

Direct Dial: 215-965-1285

Facsimile: 215-965-1210

E-Mail: gcolby@akingump.com

Enclosures Marked-Up Copy of Amended Claims
Clean Copy of Claims, As Amended